Timos Papagatsias: Interested in Social Media in the Hematology Space?
Timos Papagatsias, CEO of LucidQuest, shared on LinkedIn:
”Interested in social media in the Hematology space?
Download our ASH24 social media report!
Our team monitored and analyzed ASH-related posts on X (previously Twitter) before, during, and after the event. Here are some key takeaways:
Key Hashtags: mmsm led the discussion, emphasizing Multiple Myeloma, followed by lymsm and leusm. Hashtags like Med Twitter, mpnsm, Moffitt ASH24, MedEd, and Blood Journals also garnered significant traction, reflecting a broad and dynamic conversation around hematological research and treatment.
Top Discussion Themes: Data was the primary focus (~17.7%), highlighting the importance of evidence-based insights.
Efficacy followed closely (~16.2%), with Clinical Trials at ~13.7%. Additional themes around Treatments, patient perspectives, and Safety highlighted the drive towards more effective and patient-centered care.
Leading Voices: Doctors dominated the conversation (~56%), with Education-related and Media accounts contributing ~8% and ~10% respectively.
Research (~12%), Company (~2%), and Advocate (~10%) accounts were also active, while Nurses again scored low (~2%) in high-volume posts.
Audience Sentiment: The sentiment was overwhelmingly positive (~85%), celebrating the event’s educational value and novel insights.
About 10% were neutral, offering real-time updates and general information, while ~5% expressed negative feedback, primarily regarding session overcrowding and issues with the conference app.
Text Analytics: Discussions centered on patient-centric, data-driven approaches in Multiple Myeloma and Lymphoma management.
Treatments like CART therapy and Daratumumab attracted considerable attention, reflecting the growing impact of advanced therapeutics in hematology.
If you’re interested in social media coverage during conferences, send us a message at [email protected]; we cover multiple therapyareas and events!”
Stay updated with Hemostasis Today.
-
Mar 1, 2026, 05:44Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
-
Feb 28, 2026, 17:03Investing in Education, Prevention, and Lifesaving Research for a Healthier Tomorrow – AHA
-
Feb 28, 2026, 17:00Pamela Gavin: 1 in 10 Americans Live With A Rare Disease – That Is Not Rare, That Is Public Health
-
Feb 28, 2026, 16:59Thomas Rocco Jr: Exploring Agentic AI in Cardiovascular Medicine
-
Feb 28, 2026, 16:50Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease
-
Feb 28, 2026, 16:49Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
-
Feb 28, 2026, 16:46Nicolas Hulscher: Nattokinase Dissolves 84% of Amyloid Microclots In Vitro
-
Feb 28, 2026, 16:46Alfonso Tafur: Preventing Post-Hospitalization Blood Clots Using Precision Tools and Systems
-
Feb 28, 2026, 16:39Anel Karisik: Do Antidepressants Influence Swallowing Recovery After Acute Ischemic Stroke?